<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00508937</url>
  </required_header>
  <id_info>
    <org_study_id>MM3717</org_study_id>
    <nct_id>NCT00508937</nct_id>
  </id_info>
  <brief_title>Dietary Protein and Insulin Sensitivity Study</brief_title>
  <official_title>The Effects of Increased Dietary Protein Intake on Insulin Sensitivity in Stable Weight Individuals, Independent of Dietary Content of Carbohydrate and Saturated Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCSF Benioff Children's Hospital Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dairy Management Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UCSF Benioff Children's Hospital Oakland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the Dietary Protein and Insulin Sensitivity Study is to test the&#xD;
      hypothesis that increased protein in a diet with reduced carbohydrate (35% energy) can&#xD;
      ameliorate insulin resistance in the absence of weight loss, and that this effect is&#xD;
      independent of saturated fat content. Moreover, we will test whether such diets result in&#xD;
      beneficial changes in total LDL cholesterol, small, dense LDL, and HDL cholesterol that are&#xD;
      also independent of saturated fat intake.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin resistance is a major metabolic disturbance associated with excess adiposity that&#xD;
      contributes to atherogenic dyslipidemia and predisposes to both cardiovascular disease and&#xD;
      type 2 diabetes mellitus. The effects on insulin resistance of changes in dietary&#xD;
      macronutrient composition in the absence of weight loss are poorly understood. To better&#xD;
      understand these effects, we will study men and women with insulin resistance after 4 weeks&#xD;
      on a basal diet (15% protein, 55% carbohydrate, 30% fat) and 4 weeks after random assignment&#xD;
      to the basal diet or one of 4 diets with 35% carbohydrate and either 20% or 30% protein, and&#xD;
      either 7% or 15% saturated fat. At the end of each dietary period (4 weeks and 8 weeks), we&#xD;
      will draw a blood sample for detailed metabolic measurements and measure insulin sensitivity&#xD;
      by the frequently sampled intravenous glucose tolerance test (FSIGT) method. In addition to&#xD;
      insulin resistance, we will assess the effect of dietary composition on parameters of&#xD;
      atherogenic dyslipidemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity by Frequently Sampled Intravenous Glucose Tolerance test</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL peak particle size</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL subclasses</measure>
    <time_frame>4wks and 8wks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B</measure>
    <time_frame>4wks and 8wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein A1</measure>
    <time_frame>4wks and 8wks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">660</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 27 and ≤ 40 kg/m2&#xD;
&#xD;
          -  HOMA-IR ≥ 2.5&#xD;
&#xD;
          -  Non-smoking&#xD;
&#xD;
          -  Total cholesterol and LDL cholesterol &lt;95th percentile for sex and age&#xD;
&#xD;
          -  Fasting triglycerides &lt; 500mg/dl&#xD;
&#xD;
          -  Fasting blood sugar &lt; 126&#xD;
&#xD;
          -  Urinary microalbumin &lt; 30 mg/L&#xD;
&#xD;
          -  Normal thyroid stimulating hormone levels&#xD;
&#xD;
          -  Hematocrit ≥ 36%&#xD;
&#xD;
          -  Blood pressure &lt; 150/90&#xD;
&#xD;
          -  At least 3 months of a weight-stable state (± 5 lbs) prior to the study. During the&#xD;
             study, subjects will be required to maintain their body weight within ± 3% (up to a&#xD;
             maximum change of 5 lbs) of their initial weight over the course of any consecutive&#xD;
             two weeks after the second week of baseline diet or during the last week of each diet&#xD;
             phase&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of coronary heart disease, cerebrovascular disease, peripheral vascular&#xD;
             disease, bleeding disorder, liver or renal disease, diabetes, lung disease, HIV, or&#xD;
             cancer (other than skin cancer) in the last 5 years&#xD;
&#xD;
          -  Use of drugs known to affect lipid metabolism or insulin resistance, hormones, or the&#xD;
             blood thinning agent, warfarin&#xD;
&#xD;
          -  Use of alcohol or dietary supplements during the study&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M Krauss, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Benioff Children's Hospital Oakland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cholesterol Research Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 26, 2007</study_first_submitted>
  <study_first_submitted_qc>July 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2007</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diet</keyword>
  <keyword>Protein</keyword>
  <keyword>Glucose</keyword>
  <keyword>Insulin</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>LDL subclasses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

